Agios Pharmaceuticals IncNASDAQ:AGIO
- LAST PRICE46.5500
- TODAY'S CHANGE (%)-0.8300 (-1.7518%)
- Bid / Lots27.3300/ 1
- Ask / Lots48.5600/ 1
- Open / Previous Close47.1800 / 47.3800
- Day Range
- 52 Week Range
- Volume1,012,787
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGIO |
|---|---|---|
| 09:32 ET | 112061 | 47.18 |
| 09:34 ET | 200 | 47.14 |
| 09:45 ET | 500 | 47.46 |
| 09:50 ET | 500 | 47.22 |
| 09:52 ET | 570 | 47.135 |
| 09:56 ET | 400 | 47.11 |
| 09:59 ET | 600 | 47.35 |
| 10:01 ET | 1131 | 47.455 |
| 10:14 ET | 800 | 47.29 |
| 10:15 ET | 243 | 47.32 |
| 10:17 ET | 200 | 47.36 |
| 10:19 ET | 1296 | 47.385 |
| 10:21 ET | 300 | 47.4 |
| 10:28 ET | 2100 | 47.5 |
| 10:30 ET | 100 | 47.52 |
| 10:32 ET | 100 | 47.51 |
| 10:33 ET | 147 | 47.489 |
| 10:37 ET | 1700 | 47.43 |
| 10:39 ET | 100 | 47.46 |
| 10:44 ET | 600 | 47.45 |
| 10:46 ET | 600 | 47.47 |
| 10:51 ET | 300 | 47.41 |
| 10:55 ET | 700 | 47.435 |
| 10:57 ET | 200 | 47.48 |
| 11:02 ET | 300 | 47.36 |
| 11:04 ET | 1755 | 47.365 |
| 11:06 ET | 900 | 47.25 |
| 11:08 ET | 100 | 47.27 |
| 11:11 ET | 500 | 47.1 |
| 11:24 ET | 200 | 47 |
| 11:29 ET | 13591 | 46.81 |
| 11:33 ET | 1100 | 46.52 |
| 11:36 ET | 899 | 46.64 |
| 11:38 ET | 100 | 46.75 |
| 11:40 ET | 200 | 46.765 |
| 11:44 ET | 652 | 46.79 |
| 11:45 ET | 300 | 46.77 |
| 11:47 ET | 100 | 46.72 |
| 11:51 ET | 236 | 46.61 |
| 11:54 ET | 100 | 46.58 |
| 12:09 ET | 600 | 46.69 |
| 12:12 ET | 200 | 46.72 |
| 12:20 ET | 300 | 46.7 |
| 12:21 ET | 100 | 46.74 |
| 12:25 ET | 1100 | 46.76 |
| 12:27 ET | 600 | 46.7 |
| 12:30 ET | 300 | 46.65 |
| 12:32 ET | 600 | 46.63 |
| 12:38 ET | 1100 | 46.71 |
| 12:41 ET | 100 | 46.79 |
| 12:50 ET | 700 | 46.81 |
| 12:54 ET | 100 | 46.95 |
| 12:57 ET | 500 | 46.82 |
| 12:59 ET | 100 | 46.91 |
| 01:03 ET | 100 | 46.92 |
| 01:06 ET | 400 | 46.72 |
| 01:08 ET | 300 | 46.81 |
| 01:10 ET | 300 | 46.87 |
| 01:14 ET | 200 | 46.91 |
| 01:15 ET | 600 | 46.94 |
| 01:19 ET | 400 | 46.91 |
| 01:21 ET | 1280 | 46.89 |
| 01:24 ET | 844 | 46.814 |
| 01:26 ET | 100 | 46.83 |
| 01:28 ET | 100 | 46.8 |
| 01:30 ET | 700 | 46.79 |
| 01:32 ET | 1984 | 46.84 |
| 01:33 ET | 700 | 46.89 |
| 01:35 ET | 1000 | 46.96 |
| 01:37 ET | 100 | 46.96 |
| 01:39 ET | 200 | 47.01 |
| 01:42 ET | 100 | 47 |
| 01:44 ET | 100 | 47.05 |
| 01:48 ET | 300 | 46.95 |
| 01:50 ET | 355 | 46.97 |
| 01:51 ET | 200 | 46.99 |
| 01:57 ET | 400 | 46.93 |
| 02:00 ET | 100 | 46.9 |
| 02:04 ET | 200 | 46.9 |
| 02:06 ET | 450 | 46.86 |
| 02:08 ET | 200 | 46.78 |
| 02:09 ET | 200 | 46.8 |
| 02:11 ET | 400 | 46.78 |
| 02:13 ET | 2234 | 46.85 |
| 02:15 ET | 300 | 46.95 |
| 02:18 ET | 200 | 46.88 |
| 02:24 ET | 300 | 46.93 |
| 02:27 ET | 600 | 46.88 |
| 02:31 ET | 400 | 46.87 |
| 02:36 ET | 100 | 46.855 |
| 02:38 ET | 600 | 46.91 |
| 02:40 ET | 1300 | 46.93 |
| 02:42 ET | 900 | 46.95 |
| 02:44 ET | 100 | 46.91 |
| 02:45 ET | 400 | 47.01 |
| 02:47 ET | 400 | 47.04 |
| 02:51 ET | 1287 | 47.13 |
| 02:54 ET | 100 | 47.13 |
| 02:58 ET | 200 | 47.095 |
| 03:00 ET | 1200 | 47.07 |
| 03:02 ET | 100 | 47.075 |
| 03:03 ET | 1100 | 47.03 |
| 03:05 ET | 891 | 46.97 |
| 03:07 ET | 849 | 47.01 |
| 03:09 ET | 500 | 46.975 |
| 03:12 ET | 3066 | 47.02 |
| 03:14 ET | 605 | 47.04 |
| 03:16 ET | 1300 | 47.03 |
| 03:18 ET | 1880 | 47.03 |
| 03:20 ET | 300 | 47.04 |
| 03:21 ET | 2415 | 47.035 |
| 03:23 ET | 13778 | 47.17 |
| 03:25 ET | 1300 | 47.06 |
| 03:27 ET | 1200 | 47.24 |
| 03:32 ET | 200 | 47.185 |
| 03:34 ET | 3252 | 47.14 |
| 03:36 ET | 1100 | 47.18 |
| 03:38 ET | 300 | 47.105 |
| 03:39 ET | 2200 | 47.18 |
| 03:41 ET | 1844 | 47.16 |
| 03:43 ET | 886 | 47.09 |
| 03:45 ET | 1600 | 47.095 |
| 03:48 ET | 2390 | 47.1 |
| 03:50 ET | 806 | 47.12 |
| 03:52 ET | 3921 | 47.025 |
| 03:54 ET | 6412 | 47.08 |
| 03:56 ET | 8395 | 46.75 |
| 03:57 ET | 19296 | 46.81 |
| 03:59 ET | 555245 | 46.55 |
Sep 19, 2024
DJ Agios Pharmaceuticals Price Target Maintained With a $55.00/Share by RBC Capital, from 9:18AM ET on Thursday Sep 19, 2024 by Dow Jones
9:18AM ET on Thursday Sep 19, 2024 by Dow Jones
Sep 11, 2024
DJ Agios Gets FDA Orphan Designation for Tebapivat in Myelodysplastic Syndromes, from 7:28AM ET on Wednesday Sep 11, 2024 by Dow Jones
7:28AM ET on Wednesday Sep 11, 2024 by Dow JonesAgios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS), from 7:00AM ET on Wednesday Sep 11, 2024 by Dow Jones
7:00AM ET on Wednesday Sep 11, 2024 by Dow Jones
Sep 5, 2024
Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024, from 7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agios Pharmaceuticals Inc | 2.7B | -7.2x | --- |
Celldex Therapeutics Inc | 2.7B | -15.0x | --- |
SpringWorks Therapeutics Inc | 2.6B | -7.7x | --- |
Janux Therapeutics Inc | 2.6B | -54.9x | --- |
Protagonist Therapeutics Inc | 2.7B | 17.9x | --- |
Edgewise Therapeutics Inc | 2.8B | -18.4x | --- |
Company Information
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Contact Information
- Headquarters
- 88 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-649-8600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jacqualyn Fouse
- Chief Executive Officer, Director
- Brian Goff
- Chief Financial Officer
- Cecilia Jones
- Chief Legal Officer
- James Burns
- Chief Medical Officer, Head - Research and Development
- Sarah Gheuens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
|---|---|
Revenue (TTM) | $31.3M |
Shares Outstanding | 56.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-6.49 |
Book Value | $14.50 |
P/E Ratio | -7.2x |
Price/Sales (TTM) | 86.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,293.88% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
